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Tumorigenesis is not only determined by the intrinsic properties of cancer cells but also by their interactions with
components of the tumor microenvironment (TME). Tumor-associated macrophages (TAMs) are among the most
abundant immune cells in the TME. During initial stages of tumor development, macrophages can either directly
promote antitumor responses by killing tumor cells or indirectly recruit and activate other immune cells. As genetic
changes occur within the tumor or T helper 2 (TH2) cells begin to dominate the TME, TAMs begin to exhibit
an immunosuppressive protumor phenotype that promotes tumor progression, metastasis, and resistance to ther-
apy. Thus, targeting TAMs has emerged as a strategy for cancer therapy. To date, TAM targeting strategies have
focused onmacrophage depletion and inhibition of their recruitment into the TME. However, these strategies have
shown limited therapeutic efficacy, although trials are still underway with combination therapies. The fact that
macrophages have the potential for antitumor activity has moved the TAM targeting field toward the development
of TAM-reprogramming strategies to support this antitumor immune response. Here, we discuss the various roles
of TAMs in cancer therapy and their immunosuppressive properties, as well as implications for emerging check-
point inhibitor–based immunotherapies. We review state-of-the-art TAM-targeting strategies, focusing on current
ones at the preclinical and clinical trial stages that aim to reprogram TAMs as an oncological therapy.
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Introduction
Tumor-associated macrophages (TAMs) are among
the most abundant immune cells in the tumor
microenvironment (TME).1–3 Originally, they were
thought to be antitumoral, owing to their ability to
kill tumor cells in vitro.4–6 Indeed, at the earliest
stages of tumor onset, the immune system may
promote activation of T cells and macrophages to
clear tumor cells.7 However, once a tumor pro-
gresses past an initial stage, the TME is influenced
by cancer cells to provide support for their growth,
and even though there may still be antitumor
macrophages present, the majority of macrophages
are “educated” to enhance tumor progression and
metastasis (Fig. 1).
High infiltration of TAMs (as demonstrated by
an accumulation of macrophage-related growth
factors/chemokines/cytokines,8–12 and/or large
numbers of macrophages in tumors1,9,13–18) cor-
relates with poor prognosis and reduced patient
survival in several different types of cancer, includ-
ing human breast, gastric, oral, ovarian, bladder,
and thyroid cancers, non-small cell lung carcinoma
(NSCLC), and Hodgkin’s lymphoma.19–21 Consis-
tent with those correlative data, in vivo experiments
in mouse models of cancer have indicated that
TAMs are protumoral. Originally, these conclusions
were derived from genetic ablation of Csf1 (which
expresses macrophage colony–stimulating factor 1
required for macrophage survival and maturation)
and, thereby, elimination of macrophages in a
mammary carcinomamouse model, which resulted
in delayed tumor development and reduced pul-
monary metastasis.22 Reciprocally, transgenic
expression of Csf1 in wild-type and Csf1-null mice
accelerated tumor invasive behavior, leading to
pulmonary metastasis increase.22 Similar data
have been obtained in many other mouse models
doi: 10.1111/nyas.14377
1Ann. N.Y. Acad. Sci. xxxx (2020) 1–24 © 2020 The Authors. Annals of the New York Academy of Sciences
published by Wiley Periodicals LLC on behalf of New York Academy of Sciences
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in
any medium, provided the original work is properly cited.
Macrophage targeting in cancer Lopez-Yrigoyen et al.
Figure 1. Macrophages can promote an antitumor response, but these responses are abrogated as As T helper 2 (TH2) cells
start dominating the TME. Macrophages can promote an antitumor response (red boxes) by directly phagocytosing and/or
killing tumor cells, or indirectly by recruiting and/or presenting tumor antigens to activate other immune cells. These antitumor
responses, however, are abrogated as TH2 cells start dominating the TME. TAMs then exhibit an immunosuppressive phenotype
(blue boxes) that resembles that of macrophages involved in tissue development and repair, thereby aiding in tumor progression
and metastasis.
of cancer using similar or different strategies for
macrophage ablation.2,23,24 Together, the data sug-
gest that TAMs, in bothmouse and human contexts,
promote tumor progression to metastasis (Fig. 2).
TAMs ontogeny in the TME: breaking the
dogma
The origin of tissue-resident macrophages
(TRMs) in adults was thought to be restricted
to the mononuclear phagocytic system, whereby
hematopoietic stem cells differentiate to common
myeloid progenitors, that in turn differentiate to
granulocyte-monocyte progenitors, that give rise to
monocyte-dendritic progenitors, that differentiate
to monocytes and then into macrophages.25 How-
ever, this view has been shown to be inadequate, as
several groups using lineage tracing methods have
shown that TRMs can be derived from three devel-
opmentally distinct sources: embryonic precursors
from the yolk sac, embryonic precursors from fetal
liver (after seeding from the yolk sac), and post-
natally from monocytes derived by hematopoiesis
primarily in the bonemarrow (BM).26–31 Consistent
with these diverse origins in normal development,
TAMs—considered to be exclusively derived from
monocytes that infiltrate a tumor—have also been
shown to originate from yolk sac–derived TRMs.
For example, in pancreatic ductal adenocarcinoma
(PDAC) in mice, both inflammatory monocytes
and TRMs are TAM sources.32 Zhu et al. demon-
strated that TAMs of embryonic origin were able
to proliferate in situ during tumor progression, and
that they are transcriptionally different from TAMs
derived frommonocytes. In the lung, embryonically
derived tissue-resident interstitial macrophages
largely contribute to the pool of TAMs, and their
accumulation associates with tumor growth.
CCR2+-dependent monocytes also contribute to
the TAM pool, but they seem to be associated with
tumor spread rather than growth.33 By contrast,
in lung metastases models, metastasis-associated
macrophages (MAMs) are exclusively derived from
monocytes.34,35 Furthermore, in MMTV-PyMT
tumors (a mouse mammary tumor model), TAM
origin is exclusively from monocytes.36,37
Data regarding the origin of TAMs in the brain
are conflicting; some groups found that resident
microglia are the main source of glioma-associated
macrophages,38 while others claim that monocytes
are the main source.39 It has been highlighted that
there are technological caveats with the models
to study the origin of glioma TAMs; for example,
experiments that have used irradiation might pro-
mote bias because irradiation causes the disruption
of the blood–brain barrier, which could result in an
increased accumulation of monocyte-derived
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Figure 2. Protumormacrophages are immunosuppressive. Immunosuppressive TAMs express immune checkpoint ligands, such
as programmed-death ligand 1 (PDL1) and B7 ligands, which directly inhibit cytotoxic T cell functions. T cell cytotoxicity can
also be directly inhibited by macrophage-mediated tryptophan depletion (macrophage indoleamine 2,3-dioxygenase (IDO) is
the rate-limiting enzyme in the degradation pathway of tryptophan). Protumor macrophages secrete prorestorative cytokines
TGF-β (transforming growth factor beta), interleukin (IL)-10, and PGE2 (prostaglandin E2), which leads to downregulation of
MHC class II (major histocompatibility complex II), and thus, a diminished TH1 differentiation and in the expansion of Treg
cells (regulatory T cells). TAMs also promote immune suppression through the recruitment of TH2 cells and Treg cells by the
production of chemokines, such as chemokine ligand (CCL) 17 and CCL22. Protumor neutrophils are recruited by IL-8, CXCL13
(C-X-C motif chemokine ligand 13), CCL16, and CCL18. γδ T cells accumulate in the TME via macrophage secreted IL-1 and
WNT pathway–associated molecules,235,236 and these cells recruit protumor neutrophils via IL-17.237,238
TAMs.40 A recent publication on single cell
sequencing of human gliomas identified two TAM
subsets: one that presumably has an embryonic
tissue–resident origin, as the gene expression pro-
file showed an enrichment of microglial genes, and
a second subset that indicates an adult BM–derived
monocyte origin.41 Adult monocyte–derived TAMs
have altered metabolism, upregulated immunosup-
pressive cytokines, and a gene signature that corre-
lates with poor survival in low-grade glioma. These
findings suggest that while monocyte-derived
TAMs significantly infiltrate the tumor, they do not
entirely adopt the phenotype of microglial-derived
TAMs.
It is now becoming evident that TAMs from
different developmental origins and pathways have
both overlapping and distinct functions within
the same tumor. However, the origin of many of
the TAM populations assessed in human patients,
and even in some mouse studies, is not known.
What is relatively clear, however, is that elucidating
TAM ontogeny will help to inform therapeutic
approaches. For example, a recent publication42
using single-cell sequencing suggested that two dis-
tinct TAM subsets in colorectal cancer arise from
either monocytes or TRMs and have different gene
signatures. The equivalent murine TAM subsets
were shown to have differential sensitivity to CSF1R
blockade; anti-CSF1R treatment mainly depleted
the TAM subset that emerged solely from mono-
cytes, sparing TAMs with an angiogenic-related
signature that most likely emerged from TRMs.42
Direct protumor activities of TAMs
In this section, we give a brief overview of protumor
functions of TAMs (which have also been covered
in several excellent reviews2,23,43–46). TAMs are
involved in angiogenesis, which is an important
part of a tumor’s ability to expand and metastasize.
Depletion of TAMs by abrogating Csf1 expression
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in a mammary cancer mouse model blocked the
“angiogenic switch,” a characteristic of the tran-
sition from benign to malignant tumors,47 while
depletion of Tie2+ TAMs inhibited glioma neo-
vascularization in the mouse brain.48,49 Genetic
restoration of the macrophage populations in the
tumors from both models rescued the blood vessel
phenotype.
Hypoxia is a major driver of angiogenesis,
and hypoxic areas attract TAMs by the release
of hypoxia-induced chemoattractant molecules,
such as C-X-C motif chemokine ligand (CXCL) 4,
chemokine ligand (CCL)-2, vascular endothelial
growth factor (VEGF), and others.50 TAMs respond
to hypoxia by upregulating hypoxia-inducible tran-
scription factors and their downstream targets,
which include a wide range of proangiogenic
factors, such as transforming growth factor-beta
(TGF-β) and others.50–54
Macrophages accumulate at the invasive front of
tumors during malignant transformation22,55; these
macrophages directly help tumor cells escape from
primary tumor sites into blood or lymphatic vessels.
TAMs aid in the epithelial–mesenchymal transition
(EMT) of tumor cells in which tumor cells lose
cell–cell junctions and acquire a motile mesenchy-
mal phenotype.56 TAMs contribute to the EMT
process by secreting soluble factors, such as inter-
leukin (IL)-1β, IL-18, tumor necrosis factor alpha
(TNF)-α, TGF-β, and others,57–59 as well as extra-
cellular matrix (ECM)–degrading proteins, such
as cathepsins, metalloproteinases (MMP7, MMP2,
and MMP9), and serine proteases that allow
migration of the tumor cells.60 Other macrophage-
mediated tumor invasion–related factors include
osteonectin, which plays a role in collagen fiber
deposition and expression of MMPs,61 and Wnt5a,
which stimulates cancer cell motility.62 Also
secreted by TAMs, the protein SPARC (secreted
protein acidic and rich in cysteine) is required for
the migration of tumor cells, as its genetic abla-
tion leads to a decrease in metastasis.63,64 SPARC
supports fibronectin and vitronectin interactions
with tumor cell–expressed integrins, which leads
to a traction force along ECM fibers that allows
tumor cells to travel through the stroma toward the
vasculature.64,65
A tripartite arrangement of Tie2+ TAMs, tumor
cells, and endothelial cells, the TME of metastasis
(TMEM) is involved in tumor cell intravasation—
the presence of the TMEM, for example, is a
predictor of poor prognosis in breast cancer.66 Pro-
cesses in the TMEM are in some cases mediated by
a paracrine loop that involves the production and
secretion of EGF family ligands by macrophages to
promote tumor cell migration, and the production
of CSF1 by tumor cells to promote macrophage
recruitment and survival.55,67 Furthermore, Tie2+
TAMs in the TMEM express and secrete vascu-
lar endothelial growth factor A (VEGFA), which
causes local loss of vascular junctions and transient
vascular permeability that allows for escape of
tumor cells.68 Once tumor cells have escaped into
the blood or lymphatic circulation, they evade
immune system recognition and attack, thereby
gaining the means to survive and proliferate in
new environments.69 Macrophages and/or their
progenitors recruited from the BM are key players
in the formation of premetastatic niches, as they
help tumor cells evade immune cell recognition
and they aid in the preparation of distant sites for
tumor cells to colonize.69,70 Pre-metastatic niches
are created by systemic influences of primary
tumors acting in part through the BM and, locally,
via ECM formation that results in the recruitment
of myeloid cells, including monocytes, which then
differentiate in situ; they are attracted by secreted
factors CCL2, CSF1, VEGF, TNF-α, TGF-β, and
tissue inhibitor of metallopeptidase-1, as well as by
exosomes.70–73 Myeloid cells in the premetastatic
niche attract tumor cells by secreting chemokines
and then remodeling the ECM (via MMPs, inte-
grins, and lysyl oxidase) to promote angiogenesis,
EMT, and extravasation. This enhances both tumor
cell tropism and their abilities to seed and survive.72
Once tumor cells arrive at these metastatic sites,
a distinct population of macrophages known as
MAMs promotes the extravasation of tumor cells
and their persistent growth. Depletion of this dis-
tinct population leads to a decrease in the tumor
cell extravasation rate and, thereby, a failure of
establishment of new metastases,74 which leads, in
some cases, to improved survival of animals.34,74–76
MAMs are recruited by CCL2:34 activation of the
CCL2–CCR2 axis triggers a chemokine cascade
(including CCL3) that results in maturation of
MAMs and adhesion via α4 integrin to vascular cell
adhesion molecule 1 (VCAM-1) expressed on the
surface of tumor cells. Adhesion activates PI3K–Akt
survival signaling77,78 that facilitates lungmetastatic
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seeding by breast cancer cells.75 In prostate
cancer, bone metastases triggering the CCL2–
CCR2 axis promotes the activation of osteoclasts,
which leads to enhanced bone resorption and, in
turn, the liberation of entrapped growth factors that
stimulate the generation of other bonemetastases.79
Furthermore, as in lung metastases, MAM binding
to VCAM-1 delivers a survival signal that leads to
the protection of cancer cells from proapoptotic
cytokines, such as TNF-related apoptosis-inducing
ligand.77 In addition to the protumor functions
of TAMs or MAMs that directly enhance cancer
malignancy, other TAM/MAM activities can regu-
late other immune cells, such as T cells, to attenuate
their otherwise antitumor activity (Fig. 2).35,76 Fur-
thermore, TAMs/MAMs can limit the effectiveness
of classical cancer therapies, such as chemo- and
radiotherapy, as well as biological therapies, includ-
ing immuno-oncological therapies (Fig. 1). These
data suggest that targeting TAMs and/or MAMs
would be an effective strategy in cancer therapy.
In the remainder of our review, we concentrate
on the roles of TAMs in anticancer therapies, both
classical and immunological. We will discuss TAM
immunosuppressive properties and the implica-
tions of this on emerging checkpoint inhibitor–
based immunotherapies. Importantly, we review
the state-of-the-art of TAM-targeting strategies,
focusing on current strategies at the preclinical and
clinical trial stages that aim to reprogram/reeducate
TAMs as an effective oncological therapy.
TAMs and therapy
TAMs impair cancer standard therapy
response
TAMs are able to mediate resistance to
chemotherapy.80 For example, inhibiting CSF1
activity can reverse chemoresistance of human
breast cancer cell lines in xenograft mouse
models.81 Other work has shown that breast cancer
murine models treated with paclitaxel and anti-
CSF1 receptor signaling antagonists had reduced
tumor burden and increased T cell infiltration
when compared with models treated with paclitaxel
only.82 Furthermore, biopsies from cancer patients
undergoing neoadjuvant therapy show higher
numbers of macrophages in tumors compared with
cancer patients who receive only surgery.83
Chemotherapeutic agents, such as 5-fluorouracil
(5-FU) and doxorubicin, affect TAM phenotypes.
In colorectal cancer, 5-FU promotes macrophage
secretion of diamine putrescine, which prevents
tumor cell apoptosis.84 It also causes CCL22–
PI3K–AKT signaling activation in TAMs that
stimulates migration and invasion of tumor cells.85
Doxorubicin treatment leads to the accumula-
tion of perivascular TAMs that express VEGF
and supports angiogenesis, leading to enhanced
tumor invasion.80 Inhibiting the recruitment of
TAMs led to a reduced rate of tumor relapse after
chemotherapy.
Radiotherapy aims to target cells that have com-
promised DNA repair mechanisms (e.g., tumor
cells), but certainly it also affects normal cells
in the microenvironment. It has been shown
that irradiated macrophages remained viable and
metabolically active, with a proinflammatory phe-
notype (as there is upregulation of proinflammatory
macrophage markers CD80, CD86, and HLA-DR
and downregulation of prorestorative macrophage
markers CD163, MRC1, VCAM, and IL-10). How-
ever, these irradiated macrophages are still able to
promote angiogenesis and tumor cell invasion.86
Furthermore, during irradiation-induced wound
repair, growth factors and chemokines, such as
IL-1, TNF-α, and TGF-β, recruit macrophages
with a tissue repair–associated phenotype; and this
contributes to tumor recurrence.87
TAMs can enhance standard therapy
responses
In contrast to the above, TAMs can also con-
tribute to the therapeutic efficacy of standard anti-
cancer strategies.88 The chemotherapeutic agent
cyclophosphamide induces the secretion of CCL4,
IL-8, VEGF, and TNF-α by treated tumor cells in a
model of refractory B cell leukemia. These factors
induce macrophage infiltration in the BM and
increase phagocytic activity.89 Even though a high
density of TAMs is associated with poor prognosis
and distant metastasis in PDAC, this association is
lost in patients who have undergone postsurgical
adjuvant chemotherapy.90 This can be explained
by both a decreased number of protumoral TAMs,
as there were fewer CD206+ and IL-10+ TAMs at
the tumor–stroma interface, and in vitro experi-
ments showing that gemcitabine-treated macro-
phages show increased expression of cytotoxic
activity–related genes, thus consistent with the
macrophages becoming more tumoricidal.90 In
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colorectal cancer patients, high TAM abundance
has been associated with better disease-free sur-
vival, but only when patients had undergone 5-FU
adjuvant therapy.91 In vitro experiments showed
that there was a synergistic effect of macrophage
presence and 5-FU treatment on colorectal cancer
cell death.91
Regarding radiotherapy, low-dose γ-irradiation
in various murine models causes normalization of
aberrant vasculature, enhances the recruitment of
T cells, and causes prolonged survival.92 Low-dose
γ-irradiation was also shown to promote the differ-
entiation of monocytes and macrophages toward
an iNOS+ antitumor macrophage phenotype, and
with expression of T cell–attracting chemokines and
suppression of angiogenic and immunosuppressive
factors. In thismodel, therefore,macrophage activa-
tion promoted T cell recruitment and cytotoxicity.92
TAMs are immunosuppressive
Revolutionizing the field of oncology, immunother-
apeutic approaches increase cancer survival by
stimulating the tumoricidal abilities of cytotoxic
lymphocytes. Immune checkpoint inhibitor–based
therapies targeting programmed death 1 (PD1),
programmed death ligand 1 (PDL1), and cytotoxic
T lymphocyte antigen 4 (CTLA-4) axes can rein-
vigorate T cell recognition and cytotoxicity against
tumor cells. However, their effectiveness relies on
the presence of baseline patient immune responses
that are “unleashed” after immunotherapy to kill
cancer targets, a concept recently summarized by a
“hot” and “cold” tumor paradigm.2,93,94 Hot tumors
are characterized by high infiltration of cytotoxic T
cells that are anergic; T cell checkpoint inhibition
therapies are most effective against these tumors.
Cold tumors are characterized by the absence of
T cells at the tumor bed and edges; they are the
most challenging to eradicate and are associated
with poor prognosis, as T cell priming fails.94
Cold tumors, moreover, are characterized by low
mutational burden, poor antigen presentation, and
tumor-intrinsic insensitivity to T cell–mediated
killing.95
Currently, it is estimated that only 20–40% of
cancer patients respond to immunotherapy.96 The
mechanisms behind immunotherapy resistance can
be classified as tumor cell–intrinsic, which includes
absence of tumor cell antigenic proteins, and insen-
sibility to T cells, and tumor cell–extrinsic, which
includes the absence of T cells, the presence of
additional inhibitory immune checkpoints, and/or
the presence of immunosuppressive cells, such as
TAMs (reviewed in Refs. 2, 97, and 98).
The presence/absence of T cells in conjunction
with the presence of immunosuppressive cells has
led to further subdivision of the hot and cold tumor
dichotomy.95 Tumors defined as altered–excluded
are characterized by no T cell infiltrate inside the
tumor bed but an accumulation of the cells at the
invasive margin; although there is an intrinsic abil-
ity of the immune system tomount aT cell response,
the tumor escapes because there is a physical barrier
hindering T cell infiltration. This physical barrier
can be TAMs, as they can promote T cell trapping
at the border of the tumors by forming long-lasting
interactions with CD8+ T cells.99,100
Tumors defined as altered–immunosuppressed
are characterized by poor, although not absent, T
cell infiltration due to the presence of an immuno-
suppressive environment (e.g., myeloid-derived
suppressor cells (MDSCs),101 TAMs, and/or regu-
latory T cells) within the tumor. Preclinical studies
have demonstrated that resistance to immune
checkpoint therapy can be circumvented by tar-
geting macrophages with CSF1R inhibitors in
colorectal cancer.102 Furthermore, a combination of
anti-PD1 and anti–CSF1R was shown to induce the
regression of transplant BRAFV600E–driven mouse
melanomas.103 Depletion of TAMs restored T cell
migration and infiltration and improved the efficacy
of anti–PD1 immunotherapy in lung squamous cell
carcinoma altered–excluded tumors.99
TAM-mediated immunosuppression mecha-
nisms. In therapeutic situations, TAMs can
promote an antitumor response by directly phago-
cytosing and/or killing tumor cells or, indirectly,
by recruiting and/or presenting tumor antigens
to activate cytotoxic T cells and natural killer
(NK) cells (Fig. 3). For example, treatment of
murine cancer models with CCL16, Toll-like
receptor (TLR) 9 ligand CpG, and anti-IL-10
receptor antibodies led to an accumulation of
macrophages at the site of the tumor, as well as
macrophage cytokine secretion. This, in turn,
caused immune system activation and impairment
of tumor growth and metastasis.104 Treatment of
murine breast cancer models with granulocyte-
macrophage colony-stimulating factor (GM-CSF)
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Figure 3. Macrophages exert antitumor functions by promot-
ing immune activation. Macrophages can promote an antitu-
mor response by directly phagocytosing and/or killing tumor
cells by ADCC. They can promote antitumor response indi-
rectly by recruiting activated immune cells, such as antitu-
mor neutrophils via IL-8, NK cells, and CD8+ T cells and/or
by presenting tumor antigens to activate cytotoxic T cells.
Macrophages can also indirectly inhibit Treg cell accumulation
in the TME.
also led to an impairment of tumor growth and
metastasis by blocking macrophage VEGF activity
and reducing protumoral macrophage cytokines
IL-10 and IL-4.105 However, these antitumor
responses are abrogated in the T helper type 2 (TH2)
cells dominating the TME.1,23 Under these condi-
tions, TAMs exhibit an immunosuppressive pheno-
type that resembles the phenotype of macrophages
involved in tissue development and repair.97,106
Immunosuppressive TAMs are characterized by
a secretory profile consisting of low levels of inflam-
matory cytokines, such as IL-18, IL-12, TNF-α,
and interferon gamma (IFN-γ), and high levels
of anti-inflammatory/prorestorative cytokines,
such as IL-10 and TGF-β.107 TAM and tumor
cell–derived prorestorative cytokines TGF-β, IL-10,
and PGE2 downregulate major histocompatibility
complex (MHC) class-II molecules in TAMs. This
results in diminished TH1 differentiation (which
in turn, results in decreased antitumor activity)
and expansion of regulatory T (Treg) cells, which
are key players in tumor progression.18 TAMs
also promote immune suppression through the
recruitment of TH2 and Treg cells by the production
of chemokines, such as CCL17 and CCL22,108 and
through the recruitment of eosinophils and naive
T cells by the secretion of CXCL13, CCL16, and
CCL18.108–112
TAMs express immune checkpoint ligands, such
as PDL1, PDL2, B7-1 (also known as CD80), and
B7-2 (also known as CD86), which directly inhibit
cytotoxic T cell functions.113–115 In a checkpoint
inhibitor therapy setting, such TAM ligands com-
pete with tumor cell ligands, reducing therapeutic
efficacy. T cell cytotoxicity can also directly be
inhibited by macrophage-mediated depletion of
l-arginine (which is needed for the re-expression
of the T cell receptor (TCR) after T cells have
engaged with an antigen)97 and by macrophage-
mediated tryptophan depletion (macrophages
express indoleamine 2,3-dioxygenase (IDO), a
rate-limiting catabolic enzyme in the degradation
pathway of tryptophan).115 Furthermore, catalytic
break down products of tryptophan also exert
immunosuppressive roles.116,117
Inmetastatic sites, classical monocytes differenti-
ate into a distinct, transient myeloid cell population
(metastasis-associated macrophage precursors,
or MAMPCs) that expresses mature macrophage
markers and is able to suppress the cytotoxic
activity of CD8+ T cells through a reactive oxy-
gen species–mediated mechanism.35 MAMPCs
are formally equivalent to a much-discussed but
rarely adequately defined population of monocytic
MDSCs,101 suggesting their origin in many cancer
types. Lineage tracking shows that the MAMPCs
differentiate into MAMs that also directly suppress
CD8+ T cell killing, but in this case via expression
of the CTLA4 ligands CD80 and CD86.35
The immunosuppressive properties of TAMs
and their role in impairing immunotherapeutic
responses (Fig. 2) highlight the benefit of removing
them from the TME to improve cancer therapy.
However, Hoves et al.118 recently showed that
activation of antitumor responses by macrophages
using CD40 agonists was sufficient to create a
proinflammatory environment that supported
tumor responses of T cells that were otherwise
resistant to checkpoint inhibitors. Considering that
the CD40 agonist reprogramming of macrophages
was time limited, Hoves et al. reported that cos-
timulation with inhibitory anti-CSF1R and CD40
agonist more effectively induced T cell activa-
tion because anti-CSF1R led to depletion of the
“re-programmed macrophages” before the tumor
could re-educate them back to suppressive TAMs.
This strategy was very effective in colorectal and
mammary mouse tumors preclinical models.118
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Figure 4. Therapeutic strategies aimed at changing the phenotype of TAMs from a protumoral to an antitumoral state
(macrophage reprogramming). TAM reprogramming strategies fall into two main categories: pan-reprogramming (A) and
function-based reprogramming of TAMs (B). Pan-reprogramming includes strategies that target macrophage polarization sig-
naling pathways (A1), such as using PI3Kγ inhibitors, TLR agonists, and HDAC inhibitors; and TAM-preferentially expressed
targets (A2), such as MARCO and LILRB2. Function-based reprogramming of TAMs (B) includes targeting specific TAM func-
tions, such as phagocytosis (B1), by targeting the macrophage tumor cell “do not eat me” signals SIRP1α–CD47, LILRB1–β2M,
SIGLEC10–CD24, and PD1–PDL1, and macrophage immunosuppressive activities (B2) by inhibiting macrophage SIGLEC1,
PDL1, or abrogatingmicro-RNA activity through DICER inhibition. Macrophage reprogramming leads to the secretion of proin-
flammatory cytokines, an enhancement of phagocytic ability, and macrophage-mediated immune promotion. These activities
inhibit tumor progression, metastasis, and/or resistance to therapy. HDACs, histone deacetylases; TLRs, Toll-like receptors;
PI3Kγ, phosphoinositide 3-kinase-γ; LILRB2, leukocyte immunoglobulin-like receptor-B2; MARCO, macrophage receptor with
collagenous structure; PD1, programmed cell death 1; PDL1, PD1 ligand 1; SIRP1α, signal regulatory protein-α; LILRB1, leuko-
cyte immunoglobulin-like receptor-B1; β2M, β2-microglobulin; SIGLEC10, sialic acid–binding Ig-like lectin-10; SIGLEC1, sialic
acid–binding Ig-like lectin-1; pre-miRNA, pre-micro-RNA; Treg cells, regulatory T cells.
Because macrophages can promote an antitumor
cytotoxic cell response (Fig. 3), current thera-
pies may benefit more from strategies that aim to
reprogram TAMs from a pro- to an antitumoral
state, rather than from those that aim to deplete
them. These strategies (Fig. 4) will be discussed in
detail below.
Macrophages as a therapeutic target
Previous reviews have extensively discussed
strategies to deplete or inactivate monocytes/
macrophages (by targeting the CSF1–CSF1R axis
or using bisphosphonates), as well as strate-
gies to inhibit the recruitment of monocytes/
macrophages to tumor sites (targeting CCL2–
CCR2 signaling).1,2,119 The main disadvantage of
most of these macrophage depletion/inactivation
strategies, however, is the systemic, indiscriminate
targeting of macrophages, which leaves immune
responses compromised and at a disadvantage in
fighting external insults. Also, anti-CSF1 therapy
with antibodies or small molecules leads to several
adverse effects.120 With regard to efficacy, TAM
depletion in preclinical models causes intratumor
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Table 1. Therapeutic strategies aimed at reprogramming the phenotype of TAMs from an antitumoral to a
protumoral state
neutrophils to become highly suppressive,69,121,122
which counteracts the therapeutic benefit of a
macrophage depletion approach.69,121,122
The suggestion that changing the phenotype
of TAMs from an anti- to a protumoral state
might be a superior therapeutic approach has led
the field toward developing and testing several
reprogramming strategies. Here, we have classi-
fied these TAM reprogramming strategies into
two main categories: pan-reprogramming and
function-based reprogramming of TAMs, although
these are not necessarily exclusive (Table 1). Under
pan-reprogramming, we place strategies whose
main aim is to switch/polarize TAMs from a pro-
to an antitumoral phenotype by targeting either
macrophage polarization signaling pathways or spe-
cific TAM preferentially–expressed targets/markers
(Table 1 and Fig. 4). Function-based reprogram-
ming of TAMs includes therapeutic strategies
aimed at targeting specific TAM functions, such
as phagocytosis and immunosuppression, as well
as strategies aimed at macrophage engineering
(Table 1 and Fig. 4).
Pan-reprogramming of macrophages
Targeting macrophage polarization signal-
ing pathways. HDACs. Histone deacetylases
(HDACs) are epigenetic regulators of gene expres-
sion through their activity of removing acetyl
groups on histones. HDACs regulate the expression
of many cancer initiation- and progression-related
genes. Anomalous expression of HDACs happens
in various types of cancer; high expression cor-
relates with poor prognosis and poor survival.123
Hence, several HDAC inhibitors have been made to
treat a variety of tumors and are in clinical trials.123
Recently, the selective class IIa HDAC inhibitor
TMP195 was shown to influence monocyte and
macrophage behavior. Upon treatment with
TMP195, macrophages secreted lower levels of
CCL2 and higher levels of CCL1.124 In a later
study, treatment of a macrophage-dependent,
autochthonous mouse model of breast cancer with
TMP195 caused a reduction in both tumor burden
and pulmonary metastases via altering macrophage
phenotype.125 TMP195 treatment promoted the
recruitment of monocytes and their differentia-
tion to highly phagocytic antitumor macrophages.
Moreover, when TMP195 was given in combina-
tion with chemotherapeutic agents (paclitaxel and
carboplatin), and, alternatively, in combination
with checkpoint inhibitor anti-PD1, there was an
increased therapeutic efficacy. To date, there has
been no report of TMP195 in clinical trials.
Epigenetic adjuvant therapy can also disrupt the
premetastatic niche by targeting mainly myeloid
cells. In a recent publication by Lu et al.,126 the
authors showed that after removal of primary
lung, breast, and esophageal tumors, the admin-
istration of low-dose DNA methyltransferase
and HDAC inhibitors, 5-azacytidine and enti-
nostat, respectively, inhibited the recruitment of
immunosuppressive myeloid populations (MDSCs;
see above)101 through downregulation of the
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chemokine receptors CCR2 and CXCR2. As a
result, mice that received the treatment showed
longer disease-free survival compared with mice
treated with chemotherapy.
PI3Kγ inhibitors. Phosphoinositide 3-kinase
gamma (PI3Kγ) is a leukocyte-restricted member
of the important class of lipid kinases involved in
activating many downstream signaling molecules,
particularly in response to growth factor
signaling.127 In macrophages, PI3Kγ acts as a
molecular switch that increases immunosuppres-
sive activity, while decreasing immunostimulatory
activity. Macrophage reprogramming has been
achieved by both pharmacologic inhibition of
PI3Kγ and genetic deletion of Pik3cg.128,129
Genetic ablation of Pik3cg leads to reduced
tumor growth, angiogenesis, and metastasis in m-
ouse cancer models via downregulation of hypoxic
stabilization of hypoxia inducible factor 1α and
a decrease of other TAM-related proangiogenic
factors, such as VEGF.130 Furthermore, the lack of
PI3Kγ increased the expression ofMHC-II, induced
the secretion of proinflammatory cytokines (such
as IL-12 and IFN-γ), and reduced the secretion
of immunosuppressive cytokines, such as IL-10
and arginase. The use of PI3Kγ inhibitors, such as
SF1126, has corroborated the results observed in
genetic models.128,130
In other studies, PI3Kγ pharmacological inhi-
bition/genetic depletion promoted the recruitment
and enhanced the cytotoxicity of T cells and led to
a reduction in tumor size and a lower number of
metastatic events in several cancer models (lung,
breast, and head and neck squamous cell carcinoma
(HNSCC)). Furthermore, combinatorial inhibition
of PI3Kγ and PD1 exhibited additive effects on
tumor suppression.128
Another recent study tested a PI3Kγ inhibitor in
combination with PLG-CA4, a vascular disrupting
agent. Treatment with PLG-CA4 in a mammary
carcinoma model induced the polarization of
TAMs to a protumor phenotype. However, combi-
nation treatment of PLG-CA4 and PI3Kγ inhibitor
decreased the number of protumoral TAMs and
delayed tumor growth.131 Although PLG-CA4
treatment alone caused a reduction in pulmonary
metastasis, the combination of PLG-CA4 and
PI3Kγ inhibitor was more effective. These effects
might have been partly due to enhanced cytotoxic
T cell trafficking into the tumor and to a marked
reduction of whole tumor MMP9 expression
(MMPs serve as biomarkers of tumor progression
andmetastatic spread). In the same study, combina-
tion of PLG-CA4, PI3Kγ inhibitor, andNLG919 (an
inhibitor of immune checkpoint IDO) improved
the therapeutic effect of NLG919 alone. In synergy,
these agents apparently target tumor vasculature
(PLG-CA4) and the immunosuppressive activity
of TAMs (PI3Kγ inhibitor) and promote survival
and activity of CD8+ T lymphocytes, while sup-
pressing regulatory T cells (NLG919). AZD3458
is a highly selective PI3Kγ kinase inhibitor that
remodeled the TME by decreasing the number of
TAMs and reducing the overall protein expression
of the immunosuppressive markers CD206 and
PDL1 in the 4T1 orthotopic breast tumor model.132
Moreover, AZD3458 reduced MDSC/neutrophil
activation and promoted cytotoxic T cell activation
in vivo. Combination treatment of AZD3458 with
checkpoint inhibitor anti-PD1 or anti-PDL1 had
greater antitumor effects than checkpoint inhibitor
alone in different mouse models.132
In terms of therapeutic specificity, PI3Kγ
seems to be induced by tumor cell–derived
signaling.133 This suggests that PI3Kγ inhibitors
might only affect TAMs, excluding homeostatic
macrophages.134 In the clinic, patients with lung
and head and neck cancers and low PI3Kγ activity
have better prognosis and longer survival.128 These
data suggest that PI3Kγ could be a potential, specific
therapeutic targeting strategy that could be partic-
ularly effective in combination with other agents.
Currently, PI3Kγ inhibitors in clinical trials
include IPI-549 alone or in combination with
AB928 (a dual adenosine receptor antagonist),
doxorubicin, or paclitaxel is being tested in triple-
negative breast and ovarian cancers.135 IPI-549
alone or in combination with paclitaxel and/or
bevacizumab (anti-VEGF) is also being tested in
breast and renal cancer patients;136 and IPI-549
alone or in combination with nivolumab is being
tested in patients with advanced solid tumors,
non-small cell lung cancer, melanoma, squamous
cell cancer of the head and neck, triple nega-
tive breast cancer, bladder cancer, and urothelial
carcinoma.137,138
TLR agonists. TLRs comprise one of the pat-
tern recognition receptor families that control
innate immunity.139 TLR-activating molecular
patterns include viral and bacterial nucleic acids,
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lipopolysaccharide (LPS), lipoteichoic acid, and
mannans (and others) that have been shown to
polarize macrophages toward a proinflammatory
phenotype. Activation of TLRs via synthetic ligands
has been tested in different cancer models with
the aim of switching TAMs to a tumoricidal phe-
notype in the TME. For example, local delivery of
TLR7 and TLR8 agonist 3M-052 resulted in tumor
regression in a melanoma mouse model, and this
effect was due to the change in phenotype of
TAMs.140 Furthermore, a combination of specific
TLR agonist with anti-PDL1 and anti-CTLA4
showed a synergistic effect in inhibiting tumor
growth; for example, R848, a TLR7 and TLR8 ago-
nist, when delivered to TAMs via β-cyclodextrin
nanoparticles in combination with anti–PD1 treat-
ment, led to an increased immune response in
various models.141
Since September 2015, more than 70 clinical
trials have been started to evaluate the thera-
peutic efficacy of TLR agonists in patients with
cancer, including TLR2- and TLR4-stimulating
BCG (Bacillus Calmette–Guérin), that is, a live-
attenuated Mycobacterium bovis enriched in pepti-
doglycans and unmethylated CG-containing DNA;
TLR3 agonists rintatolimod (commercially known
as Ampligen R©) and poly-ICLC (commercially
known as Hiltonol R©); TLR4 agonist G100; TLR8
agonist motolimod; TLR9 agonists SD-101, DV281
(Class C CpG-ODN), and DUK-CPG-001 (a syn-
thetic CpG-rich oligonucleotide); and TLR3 and
TLR7 agonist imiquimod.
BCG is now the gold standard immunologic
agent to treat high-grade nonmuscle-invasive blad-
der cancer.142–144 TLR8 agonist imiquimod is being
tested in phase III trials and has proven safe as a
topical agent for patients with basal cell carcinoma,
anal carcinoma, cervical intraepithelial lesions, and
other skin carcinomas.139,145 In preclinical mod-
els, lung cancer treatment with aerosolized TLR9
agonist DV281 led to a lung-localized substantial,
but transient, cytokine, and chemokine response
that was therapeutically beneficial.146 DV281 is
now in a phase 1b/2 study and was proven safe
in combination with nivolumab in patients with
advanced or metastatic NSCLC.147
TLR3 agonist poly-ICLC, TLR4 agonist G-100,
TLR8 agonist motolimod, and TLR9 agonist SD-
101 have proven safe in clinical trials. G100 used
in Merkel cell carcinoma patients increased inflam-
mation in the injected tumors, as indicated by an
increase in CD8+ and CD4+ T cells as well as
upregulation of immune-related genes; treatment
left some patients recurrence-free after 41 months
and some with sustained partial responses lasting
33 months.148 Poly-ICLC generated a local and sys-
temic immune response (i.e., an increase of CD8+
and CD4+ T cells, CD86+ antigen-presenting cells,
CD68+ macrophages/monocytes, and CD16+ NK
cells at tumor sites) that led to clinical benefit of
patients with recurrent metastatic disease (HNSCC
or melanoma).149 In combination with PD1
inhibitor pembrolizumab in patients with unre-
sectable or metastatic melanoma, SD-101 induced
immune activation at the tumor sites indicated by
increased expression of CD8+ T, NK, dendritic,
and B cell–related genes; increased immune activity
was variable among patients, but correlated with
increased clinical response.150 Motolimod in com-
bination with cetuximab in patients with recurrent
or metastatic HNSCC led to some patients achiev-
ing partial responses and some achieving disease
stabilization,151 while in combination with pegy-
lated liposomal doxorubicin in patients with recur-
rent ovarian cancer, it did not significantly improve
overall clinical outcomes. However, subset analyses
revealed significant differences of motolimod in
patients who showed immune responses in vitro.152
Thus, there is a need to develop strategies to identify
and select patients’ subsets that might benefit from
treatment with this immunomodulatory agent.
Targeting TAM-preferentially expressed tar-
gets/markers. LILRB-2. LILRB-2 belongs to the
family of leukocyte immunoglobulin-like recep-
tors (LILR).153 Inhibitory LILRB receptors are
expressed by myeloid cell populations and are pri-
mate specific. Paired immunoglobulin-like receptor
B (PirB) is the only mouse receptor orthologous to
the human LILRB/CD85 family. In murine mod-
els, PirB-deficient macrophages show enhanced
proinflammatory cytokine release and exacerbate
autoimmune disease.154 In humans, little is known
about the role of LILRBs in macrophage activation,
in part due to the poor conservation of these recep-
tors between humans and mice; however, because
LILRBs bear the immunoreceptor tyrosine–based
inhibitory motifs of PirB, LILRBs potentially mod-
ulate macrophage behavior as well. This has been
borne out experimentally. For example, in vitro,
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anti-LILRB-2 treatment increased primary human
monocyte–derived macrophage responses to LPS
and allowed for the production of inflammatory
monocyte–derived macrophages in the presence of
CSF1. This response was shown by downregulation
of CD14, CD163, and IL-10 and upregulation
of TNF-α at the protein level.155 LILRB2 antag-
onism suppressed LPS-induced PDL1 (CD274)
expression in monocytes and macrophages from
human healthy donors. In vivo, LILRB2 sup-
pression increased the efficiency of checkpoint
inhibitor anti-PDL1 for treatment of Lewis lung
carcinoma tumors. While there was a decrease
in granulocytic-MDSCs—a tumor immune sup-
pressive myeloid population101—and Treg cells
in tumors, there was an unexpected increase in
monocytic macrophage–derived suppressor cells
(M-MDSCs), another myeloid population associ-
ated with immune suppressive functions.101 The
accumulation of M-MDSCs did not compromise
the efficacy of anti–PDL1 treatment, which suggests
that LILRB-2 antagonism is polarizing M-MDSCs
to an immunostimulatory/nonimmunosuppressive
phenotype, rather than reducing their numbers.
MARCO. The macrophage receptor with col-
lagenous structure (MARCO) is a 210 kDa trimeric
membrane-bound type II glycoprotein belong-
ing to the class A scavenger receptor family.156
MARCO expression is restricted to some subsets
of macrophages in secondary lymphoid organs157;
its expression can be upregulated on homeo-
static macrophages after bacterial infection or LPS
stimulation.158–160 MARCO expression has also
been found in a subset of TAMs in melanoma,
breast, colon, and endometrial cancers,161 and,
more recently, NSCLC.162 Georgoudaki et al.
explored the potential of repolarizing MARCO-
expressing TAMs from a pro- to an antitumoral
phenotype as a potential therapy. Anti-MARCO
treatment reduced tumor growth and metastatic
spread in mammary carcinoma and melanoma
murine models. Additionally, in the melanoma
and colon cancer models, the combination of
anti-MARCO and anti-CTLA4 neutralizing anti-
bodies improved the therapeutic effects of the
treatments given on their own. This was explained
by an alteration of the composition of TAMs
in the TME, as the MARCO-expressing TAM
population switched from a tumor promoting to
an antitumor phenotype, resulting in the tumor
becoming immunogenic and thereby contributing
to the reduction of immune suppression within
the tumor. MARCO expression was restricted to
a subset of TAMs with an immunosuppressive
gene signature in mammary, colon, and melanoma
carcinoma cell line models.161 This suggests that
anti-MARCO strategies can selectively target anti-
tumor TAMs. Furthermore, a recent study of a
large cohort of human NSCLC tumors showed
that MARCO is expressed only by a subset of
TAMs.162 Interestingly, MARCO+ cells were found
to coexpress PDL1 and have a striking localization
pattern: they surround tumor islets/tumor cell
nests. This suggests that MARCO+ TAMs could
act as a physical and immunosuppressive barrier
that protects tumor cells. At the transcript level,
MARCO expression correlated with expression of
checkpoint molecules PDL1, PD1, CTLA4, and
VISTA. These observations suggest that targeting
MARCO, in combination with immune checkpoint
inhibitors, could be a potential therapy for subsets
of NSCLC patients who have a high number of
MARCO-expressing TAMs.
Function-based reprogramming of TAMs
Targeting phagocytic activity of macrophages.
Tumor cells can evade macrophage clearance by
overexpressing antiphagocytic surface proteins:
this might be a fundamental defense mecha-
nism induced in tumors that enables their sur-
vival. The most studied and documented of these
antiphagocytic signals is via CD47, which engages
with macrophage signal regulatory protein-alpha
(SIRP1α).163,164 Monoclonal antibodies or small
molecules that antagonize this interaction have
demonstrated therapeutic potential in several can-
cers; however, there is a strong variability in the
efficacy and durability of response and/or relapse,
which might be due to redundant inhibitory sig-
nals involved in immunoregulation. To date, new
antiphagocytic signals have emerged, for exam-
ple, MHC class I component beta 2-microglobulin
(β2-M) that binds themacrophage inhibitory recep-
tor LILRB1165 and CD24 that binds macrophage
sialic acid–binding Ig-like lectin (SIGLEC)-10.166
CD47 and SIRP1 axis. CD47 is a ubiqui-
tously expressed transmembrane protein with
one immunoglobulin-like (Ig-like) extracellular
domain and five transmembrane domains.167
CD47 is involved in regulating cellular activities,
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including apoptosis induction, cytokine pro-
duction, regulation of phagocytosis, cell migra-
tion, axon extension, cell–cell fusion, and T cell
activation.168–174 CD47 engages with thrombo-
spondin-1 and SIRP1α. In contrast to CD47,
SIRP1α expression is restricted to myeloid cells
(monocytes, macrophages, granulocytes, and den-
dritic cells) and neurons.167,175 SIRP1α contains
three Ig-like extracellular domains and its cyto-
plasmic domain contains tyrosine-based inhibition
motifs (ITIMs) that recruits inhibitory proteins like
Src-homology region 2–containing protein phos-
phatase (SHP) 1 and SHP2.176,177 In macrophages,
binding of SIRP1α to CD47 couples SIRP1α and
these tyrosine phosphatases, which ultimately pre-
vents phagocytosis via the functional suppression of
nonmusclemyosin IIA at the phagocytic synapse.176
In cancer, CD47 is overexpressed in a wide
variety of tumor types: from myeloid leukemia and
non-Hodgkin’s lymphoma (NHL), to solid tumors
in bladder and breast cancer.163,178–185 Several
in vitro studies have shown that blocking of CD47
with monoclonal antibodies enables macrophage
phagocytosis of tumor cells.163,178,180 Other studies
have shown that CD47 abrogation significantly
enhances the ability of macrophages to kill tumor
cells via antibody-dependent cellular cytotoxicity
(ADCC).13,186–188 In vivo, treatmentwith anti-CD47
reduces tumor burden and improves survival in a
wide variety of human tumor–engraftedmice mod-
els, thus highlighting that inhibiting CD47 may be
a successful strategy for cancer therapy.164,180,189,190
Currently, several antibodies and fusion proteins
that target the CD47–SIRP1α axis are being tested
in early phase clinical trials: Hu5F9-G4, CC-90002,
SGN-CD47M, IBI188, AO-176, and SRF231 are all
CD47 monoclonal antibodies, while CC-95251 and
BI-765063 are anti-SIRP1αmonoclonal antibodies.
Additionally, TTI-621 is a fusion protein containing
the sequences encoding theN-terminal CD47 bind-
ing domain of human SIRP1α and the Fc domain of
human immunoglobulin (IgG1); TTI-622 is similar
to TTI-621 but the Fc domain is that of human
immunoglobulin IgG4; ALX148 is a fusion protein
composed of a modified SIRP1α D1 domain and
an inactive human IgG1 Fc; and HX 009 is an
anti-PD1–CD47 bispecific antibody fusion protein.
Hu5F9-G4 treatment alone was well-tolerated
in clinical trials and led to significant clinical
improvement in patients with ovarian and fallopian
tube cancer.191 In combination with azacitidine, it
demonstrated objective responses in acute myeloid
leukemia (AML) and myelodysplastic syndrome
(MDS) patients,192 while in combination with
rituximab, it showed effectiveness in patients with
follicular- and diffuse large B cell–lymphomas.193
CC-90002 did not show significant results in a
trial for patients with AML/MDS194–196; however,
in combination with rituximab, the need for fur-
ther clinical evaluation of patients with CD20+
relapsed/refractory NHL was concluded.197 Ini-
tially, TTI-621 raised concerns regarding its safety
profile, as patients suffered frommoderate to severe
thrombocytopenia;198–200 however, later observa-
tions showed that this effect was transient and could
be reduced after multiple infusions. TTI-621 intra-
tumor injections caused ameasurable improvement
in outcomes in cutaneous T cell lymphomas.201,202
ALX148 alone or in combinationwith anti-PD1 and
anti-HER2 agents proved safe and showed objec-
tive responses in patients with late-stage NSCLC,
HNSCC, and gastric/gastroesophageal cancer.203
Current clinical trial results and the emergence of
new agents targeting the CD47–SIRP1α axis under-
score the importance of targeting the phagocytic
ability of macrophages from the TME. However,
there is room for refinement in the targeting strate-
gies against this axis. One of the main concerns
is that CD47 is also expressed by nontumor cells.
This not only explains why thrombocytopenia and
anemia are among the most common treatment-
associated side effects but also suggests that anti-
CD47 antibodies are likely to be sequestered away
from tumor cells by CD47-expressing normal cells.
Thus, there is a necessity tomonitor and ensure that
sufficient levels of anti-CD47 antibody are reached
in the blood and TME during treatment. Since
SIRP1α is more narrowly expressed than CD47,
therapeutic strategies aiming at SIRP1αmight result
in less toxicity and more effectiveness. However, it
is important to keep in mind that these agents may
affect solid tissues, such as liver, lung, and brain,
which contain large numbers of macrophages.
β2-M of the MHC-I and LILRB1 axis. Molecules
from the MHC class I are composed of a single
polymorphic heavy chain and the single light chain
β2-M.204 These molecules are known for their
antigen-presenting function to cytotoxic T cells
and subsequent triggering of adaptive immune
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response. Recently, MHC class I has been proposed
to act as an antiphagocytic signal.165 Treatment of
18 different human cancer cell lines with anti-CD47
led to variable magnitudes of macrophage phago-
cytosis; some cell lines were not phagocytosed at
all.165 These findings suggested the expression of
one or more dominant inhibitory signals besides
CD47. MHC-I proteins emerged as candidates
because there was a putative relationship between
high expression of MHC-I proteins and resistance
to CD47-induced phagocytosis. Furthermore,
human tumor cell lines that lacked both CD47 and
MHC-I were the most sensitive to macrophage
phagocytosis, when compared with cell lines
that expressed at least one or both cell-surface
proteins.
LILRB1, a receptor that contains immunorecep-
tor inhibitory motifs and is involved in intracel-
lular transduction of inhibitory signaling,205,206 is
expressed by macrophages. This receptor binds to
MHC-I, which leads to the inhibition of phagocyto-
sis. Barkal et al. demonstrated that LILRB1 specifi-
cally binds to the β2-M subunit of MHC-I, rather
than the mostly allele-specific polymorphic heavy
chain; abrogation of MHC-I, the β2-M subunit,
or LILRB1 potentiated phagocytosis of tumor cells
both in vitro and in vivo and led to an additive effect
to that of abrogation of CD47. The study by Barkal
et al. suggested that targeting two independent
antiphagocytic axes might be a promising strategy
to sensitize tumor cells to attack by macrophages.
However, to date, there are no clinical studies aimed
at modulating the LILRB1–MHC-I axis.
CD24–SIGLEC10. Sialoglycoprotein CD24 has
emerged as a novel antiphagocytic signal that binds
macrophage SIGLEC10166 and has a role in adaptive
immunity, inflammation, autoimmune diseases,
and cancer.207,208 It is overexpressed in many can-
cers and appears oncogenic. SIGLEC10 is involved
in cell–cell recognition and interaction with sialy-
lated ligands from specific cell populations.209 At
the transcript level, CD24 is very highly expressed
in nearly all tumor types,166 especially in ovarian
cancer and triple-negative breast cancer (TNBC)
tumors. Interestingly, CD24 expression is higher
than that of other well-described antiphagocytic
signals (CD47, PD1, and β2-M) in most tumor
types. Furthermore, stratification of patients by
CD24 expression showed a negative correlation
between CD24 and overall survival advantage.
Single-cell RNA-seq on TNBC samples revealed
that CD24 is a tumor-cell specific marker in the
TME and that SIGLEC10 is expressed by a substan-
tial fraction of TAMs.166 Abrogation of CD24 in
human tumor cell lines led to enhanced phagocyto-
sis by macrophages; moreover, abrogation of CD24
and blockade of CD47 had a cooperative effect, sug-
gesting that CD47 and CD24 antiphagocytic signals
do not serve redundant phagocytic functions. Abla-
tion of SIGLEC10 in macrophages also resulted
in an enhanced tumor cell phagocytosis. In vivo,
injection of CD24-deficient cells led to tumors with
reduced size and longer mouse survival compared
with injections with wild-type cells; this effect was
explained by augmented phagocytosis of infiltrating
TAMs.166 Currently, there is a phase Ib/II clinical
trial to test safety and efficacy of combining CD24Fc
(a recombinant fusion protein) with ipilimumab
and nivolumab in anti-PD1/-PDL1 naive patients
who suffer from metastatic melanoma, renal cell
carcinoma, or colon cancer.210
Targeting the immunosuppressive activity of
macrophages. TAMs are immunosuppressive
because they prevent tumor cell attack by T cells
(and NK cells) during tumor progression. In
this section, we discuss macrophage programming
strategies that lead to the recruitment/enhancement
of activated cytotoxic cells.
PDL1 and PD1 axis. Programmed cell death
protein 1 (PD1) was first discovered as an immune
checkpoint receptor that is upregulated on activated
T cells to induce immune tolerance.211–214 When
activated, PD1 triggers the phosphorylation of
downstream molecules on T cells, namely, CD28,
and mitigates the activation of the TCR.215 Since
tumor cells can overexpress the ligand for PD1
(PDL1), they are able to escape the immune sys-
tem by inhibiting T cell activation. Monoclonal
antibodies that target the interaction between PD1
and PDL1 have shown promising clinical efficacy
against a wide variety of cancers.216–222 In the
past, PD1- and PDL1-blocking antibodies were
assumed to be interchangeable and solely act by
interrupting T cell suppression. It is now suggested
that anit-PDL1 and anti-PD1 do not function
in a completely overlapping manner to promote
tumor immunotherapy, and instead anti-PDL1
exerts distinctive, T cell–independent effects on
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tumor immunity. Recent studies have revealed that
PD1 is not only expressed by T cells but also by
B cells, NK cells, dendritic cells, monocytes, and
macrophages,214,223,224 while PDL1 expression has
also been shown on TAMs.214
The PDL1–PD1 axis in TAMs is difficult to
place under one category of TAM reprogramming.
We have placed it under “targeting the immuno-
suppressive activity of macrophages,” as targeting
PDL1 in TAMs can switch their phenotype to an
antitumor one that directly leads to an increase in
T cell–mediated immune surveillance.225,226 How-
ever, targeting this axis also modulates macrophage
phagocytic ability.214 In vitro, anti-PDL1 treat-
ment of human and mouse macrophages increases
macrophage proliferation, survival, and activation,
with upregulation of proinflammatory-associated
pathways.227 In vivo, anti PD1 therapy was shown
to lead to a significant decrease in the number
of osteosarcoma lung metastases, enhanced tumor
apoptosis, and decreased tumor cell proliferation.225
Although this anti-PD1 therapy increased NK cell
and macrophage tumor infiltration, the numbers
of antitumor macrophages were increased, while
protumor macrophage numbers were decreased.
Macrophage- and NK cell–depletion experiments
showed that macrophages were responsible for
the effectiveness of the anti-PD1 treatment.225
Combined PD1–PDL1 antibody treatment in
a melanoma murine model also led to tumor
regression and enhanced survival compared with
single agent–treated and untreated animals. The
effects observed were partly explained by a reduced
immunosuppressive macrophage phenotype.227
Human andmurine colorectal TAM PD1 expres-
sion directly correlates with the expression of pro-
tumor macrophage–associated markers CD206 and
CD11c, while it inversely correlates with phagocytic
potency against tumor cells.214 Due to its effect on
macrophage, the PD1–PDL1 axis has also been pro-
posed as antiphagocytic axis. In vivo, blocking the
PD1–PDL1 interaction in a colorectal cancermouse
model, with either anti-PD1 or anti-PDL1 mono-
clonal antibodies, led to an increase in macrophage
phagocytosis, a reduction in tumor growth, and an
improved survival rate and duration.214 Depletion
of macrophages reversed the antitumor effective-
ness observed with PD1–PDL1 axis blockade. The
effects of the PD1–PDL1 blockade on macrophages
in human cancer should not be neglected by the
focus on T cell signaling, as effects on macrophages
may inform therapeutic effectiveness evaluation
and suggest other therapeutic approaches.
SIGLEC1 (CD169). SIGLEC1, also known as
sialoadhesin and CD169, belongs to the sialic
acid–binding IgG-like lectin family of proteins.228
It is expressed by subsets of macrophages in the
BM and lymphoid tissues.226 In humans, SIGLEC1
expression has been associatedwith shorter disease-
specific survival and lower recurrence-free survival
in publicly available gene expression data sets from
whole tumor homogenates.229 In breast cancer,
SIGLEC1 is one of the top upregulated genes in
human TAMs, compared with healthy breast-
resident macrophages.229 Furthermore, SIGLEC1
is upregulated by human macrophages upon their
exposure to TNBC cell lines conditioned media.229
Depletion of CD169+ macrophages in murine
TNBC models has been shown to reduce tumor
growth and decreased lung metastasis.226 Mech-
anistically, this was explained by a significant
expansion of CD8+ T cells in the circulation and
spleen, as well as an increased accumulation of these
cells within the tumors. In vitro culture of CD169+
macrophages with tumor cells caused upregu-
lation of PDL1 in macrophages, which suggests
that TAMs in the TME in vivo may help subvert
T cell–mediated immune surveillance. However,
these results may not be an effect of CD169 per se,
but from depletion of CD169-expressing TAMs.
MiR-340-5p. MicroRNAs (miRNAs) are small
noncoding RNAs of ∼22 nucleotides in length
that silence gene expression in a sequence-specific
manner.230 The maturation of miRNAs is reg-
ulated by the RNase-III enzyme DICER. TAMs
can be reprogrammed to become tumorici-
dal macrophages by the modulation of miRNA
activity,231 as conditional deletion of Dicer in
macrophages leads to hyperactive IFN-γ/STAT1
signaling and recruitment of activated cytotoxic
cells into the tumor. Because depletion of DICER
results in the loss of TAM immunosuppressive
activity and promotes the recruitment of cyto-
toxic cells, DICER is one of the regulators of the
immunosuppressive activity of TAMs.
A recent study proposed that a miR-340-
5p–mediated macrophage feedback loop is
involved in glioblastoma multiforme (GBM) tumor
progression.232 Low levels of miR-340-5p in GBM
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correlate with increased tumor size, recurrence of
GBM, and poor survival; and levels of miR-340-5p
inversely correlate with protumor TAM density
(the TAMs expressed IBA1 and CD163). In vitro,
overexpression of miR-340-5p in GBM tumor cell
lines repressed the recruitment of macrophages
and inhibited macrophage activation, resulting
in an antitumor state, as shown by a decrease
of macrophage expression of CD163, reduced
secretion of TGF-β and IL-10, and production of
high levels of proinflammatory cytokines, such as
IL-6 and TNF-α. In vivo, injection of miR-340-5p–
overexpressing cells led to lower TAMdensity in the
TME and a lower proportion of protumor TAMs,
compared with wild-type control cells; this resulted
in a reduction in intracranial tumor volume and
prolonged survival. It seems unlikely, however, that
this pathway can be targeted therapeutically.
Macrophage engineering. An additional provoc-
ative therapeutic strategy in preclinical study is the
engineering of macrophages to express chimeric
antigen receptors (CARs) to kill tumor cells. Several
academic laboratories and companies are working
on different CAR-expressing macrophage designs
to selectively target tumor antigens, such as Her2,
and trigger macrophage phagocytosis of cancer
cells.233,234 However, many more studies will be
needed to evaluate this therapeutic strategy, as
multiple limiting steps, including cell delivery,
specificity, survival, effective cancer killing, and
toxicity/adverse effects, could potentially prevent
CAR-expressing macrophages from moving to the
clinic.
Conclusions and perspectives
The protumor roles of TAMs reported in this
review strongly support the idea that targeting
macrophages in cancer is a promising therapeutic
strategy. All of the preclinical and clinical stud-
ies described above suggest that programming
macrophages to an antitumor state would be
preferential to strategies that deplete all TAMs
and/or inhibit their recruitment. Harnessing both
macrophage diversity and ability to respond to
changing environments can lead to improved ther-
apies, asmacrophages with an antitumor phenotype
can impair tumor growth via secretion of antitumor
factors, phagocytosis, and/or increased immune
infiltration, and increased cytotoxicity of T cells
and other immune cells. However, there are still
several open questions in the field of TAMs that
will need careful investigation.
One aspect is the origin of TAMs: different
studies have shown that TAMs of different develop-
mental origins accumulate within the TME.33,38,40
Although both adult BM- and yolk sac/fetal liver
embryonic–derived TAMs can be influenced by
the presence of the tumor to change their pheno-
type into protumor cells, they show differences in
gene expression profiles.41 Studies are needed to
investigate the interplay of these two populations
in tumor progression, invasion, and resistance to
therapy, and to answer the following questions:
(1) Do TAMs from distinct developmental origins
share the same protumor functions? (2) Do they
localize in different tumor areas? (3) Can TAMs of
embryonic origin proliferate within a tumor? (4)
If TAMs of embryonic origin are depleted, could
TAMs from adult BM origin replace them, and vice
versa? (5) Are TAMs of a specific developmental
origin more susceptible to depletion and/or repro-
gramming? To answer these questions, strategies to
refine single-cell RNA-sequencing approaches and
identify specific markers that distinguish and track
TAMs from different origins in mouse and human
tumors are needed, like the strategies presented by
Zhang et al.42
A second aspect that requires attention concerns
TAM heterogeneity and localization within the
tumor area: TAMs can assume different phenotypes
depending on their location in a tumor—that is,
perivascular, near immune cell–rich or hypoxic
areas—however, very little is known about human
TAMsubset interactionswith other immune cells in
the presence or absence of therapy. Novel technolo-
gies, such as spatial transcriptomics and multiplex
immunofluorescence, will likely be pivotal for iden-
tifying novel TAM subsets and understanding their
function within the TME.
A third aspect requiring attention is the need
to compare the TME composition before and after
therapy. Are there specific subsets of TAMs that
promote therapy resistance? Are these subsets
from the same developmental origin? What ther-
apeutic changes are needed to reprogram resistant
macrophages to an antitumor phenotype?
Finally, one of the most important aspects will
be to investigate the therapeutic clinical efficacy
of TAM targeting, mainly in combination with
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checkpoint inhibitors, such as anti-PD1 and anti-
CTLA4. The challenges for researchers and clini-
cians will be to find the right targeting strategy, the
right timing for the treatment, and the best TAM
targets for synergizing with current immunother-
apies. Which strategies will be the ones that allow
targeting of only the protumor functions of TAMs,
while keeping the innate antitumor macrophage
properties unaltered? Future studies have a lot to
teach us about the fascinating biology of TAMs.
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